Recurrent Lung Non-Small Cell Carcinoma Clinical Trial
Official title:
Pilot Phase II Study of 5-Azacytidine in Previously Treated Patients With Advanced NSCLC
This phase II clinical trial is studying how well azacitidine works in treating patients with previously treated advanced non-small cell lung cancer. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
PRIMARY OBJECTIVES:
I. To determine the ability of 5-azacytidine to cause DNA hypomethylation and re-expression
of silenced tumor suppressor genes when stratified for high or low expression of mir29a, b,
and c.
SECONDARY OBJECTIVES:
I. To compare the molecular studies (mir29 expression and tumor suppressor gene methylation)
between archival tissue, fresh biopsy pre-treatment samples, and post-treatment fresh
samples.
II. To determine the overall response rate by CT (RECIST 1.1 criteria) and PET (EORTC PET
response criteria), PFS, and OS of patients treated with azacytidine in the second- or
third-line setting.
III. To correlate the blood microRNA profiles (and changes in microRNA profiles) with
response to azacytidine.
OUTLINE:
Patients receive azacitidine subcutaneously on days 1-7. Courses repeat every 28 days in the
absence of disease progression or unacceptable toxicity.
Patients undergo tissue and blood sample collection at baseline and periodically during study
treatment for correlative studies. After completion of study treatment, patients are followed
up for 12 weeks.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04151940 -
PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
|
N/A | |
| Recruiting |
NCT01629498 -
Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients With Stage II-IIIB Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT00254384 -
Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery
|
Phase 1 | |
| Terminated |
NCT01912625 -
Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
|
Phase 1 | |
| Active, not recruiting |
NCT04250545 -
Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT04919369 -
All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT03600701 -
Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT01725165 -
Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04514484 -
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
|
Phase 1 | |
| Recruiting |
NCT05234307 -
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT04533451 -
Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT03987555 -
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
|
||
| Recruiting |
NCT05642572 -
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
|
Phase 2 | |
| Active, not recruiting |
NCT03971474 -
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
|
Phase 2 | |
| Active, not recruiting |
NCT02496663 -
Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
|
Phase 1 | |
| Active, not recruiting |
NCT04227028 -
Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC
|
Phase 1 | |
| Active, not recruiting |
NCT02503722 -
Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT04837716 -
Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT03066206 -
Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC
|
Phase 2 | |
| Active, not recruiting |
NCT05096663 -
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
|
Phase 2/Phase 3 |